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STUDY PROTOCOL Open Access
Scaling up Quality Improvement for
Surgical Teams (QIST) – avoiding surgical
site infection and anaemia at the time of
surgery: protocol for a cluster randomised
controlled trial
Ashley B Scrimshire1,2* , Alison Booth1, Caroline Fairhurst1, Mike Reed2, Win Tadd3, Annie Laverty2,
Belen Corbacho1, David Torgerson1 and Catriona McDaid1
Abstract
Background: Measures shown to improve outcomes for patients often fail to be adopted into routine practice in
the NHS. The Institute for Health Improvement Breakthrough Series Collaborative (BSC) model is designed to support
implementation at scale. This trial aims to assess the effectiveness and cost-effectiveness of quality improvement
collaboratives (QICs) based on the BSC method for introducing service improvements at scale in the NHS.
Methods: Forty Trusts will be randomised (1:1) to introduce one of two protocols already shown to improve outcomes
in patients undergoing elective total hip and knee replacement surgery.
The intervention is improvement collaboratives based on the BSC model, a learning system that brings together a
large number of teams to seek improvement focussed on a proven intervention. Collaboratives aim to deliver at scale,
maximise local engagement and leadership and are designed to build capacity, enable learning and prepare for
sustainability. Collaboratives involve Learning Sessions, Action Periods, and a summative congress.
Trusts will be supported to introduce either: decolonisation for Methicillin Sensitive Staphylococcus aureus (MSSA) to
reduce post-operative infection (QIST: Infection), or an anaemia optimisation programme to reduce peri-operative
blood transfusions (QIST: Anaemia). Trusts will continue with their usual practice for whichever protocol they are not
introducing. Anonymised data related to both infection and anaemia outcomes for patients undergoing hip or knee
arthroplasty at all sites will mean that the two groups act as controls for each other.
The primary outcome for the QIST: Infection collaborative is deep MSSA surgical site infection within 90 days of surgery,
and for the QIST: Anaemia collaborative is blood transfusion within 7 days of surgery. Patient-level secondary outcomes
include length of hospital stay and readmission, which will also inform the economic costings. Qualitative interviews
will evaluate the support provided to teams.
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Discussion: The scale of this trial brings considerable challenges and potential barriers to delivery. Anticipated
challenges relate to recruiting and sustaining up to 40 organisations, each with its own culture and context. This
complex project with multiple stakeholders across a large geographical area will be managed by experienced senior-
level project leaders with a proven track record in advanced project management. The team should ensure effective
project governance and communications.
Trial registration: ISRCTN, ISRCTN11085475. Prospectively registered on 15 February 2018.
Keywords: Implementation at scale, Anaemia, Surgical site infection, Surgery, Breakthrough series collaborative
Background
Across all of healthcare there are known gaps between
what the evidence shows to be best practice and the care
that patients receive. The reasons for this are often com-
plex and multifactorial. Efforts to improve quality show
mostly inconsistent and patchy results [1–3].
Quality improvement programmes can provide a frame-
work to help bridge the evidence-to-practice gap. One tech-
nique is a quality improvement collaborative (QIC). The
general aim of any QIC is to introduce change at scale and
at pace by encouraging collaboration between teams from
different healthcare systems. The specific clinical process,
pathway or outcome being targeted can vary widely as can
the healthcare setting in which these are being imple-
mented. The Institute for Healthcare Improvement (IHI)
developed the Breakthrough Series Collaborative (BSC)
methodology as one way to design and deliver an improve-
ment collaborative.
A collaborative is a short-term (6- to 15-month) learn-
ing system that brings together a large number of teams
from hospitals or clinics to seek improvement in a
focussed topic area. Collaboratives range in size from 12
to 160 organisational teams [4]. Each team typically sends
three of its members to attend Learning Sessions (face-to-
face meetings) over the course of the collaborative, with
additional members working on improvements in the
local organisation [4]. Teams in such collaboratives have
achieved dramatic results, including reducing waiting
times by 50%, reducing worker absenteeism by 25%, redu-
cing intensive care unit costs by 25%, and reducing hospi-
talisations for patients with congestive heart failure by
50% [4]. However, this model is yet to be tested at scale in
the English National Health Service (NHS).
A systematic review of the existing evidence on QICs
highlighted the need for randomised controlled trials
(RCTs) to assess their effects on the process of care, and
provider- and patient-level outcomes [5]. In particular
the review identified a lack of evidence on whether the
procedural improvements associated with collaboratives
translate into patient-level outcomes. In a more recent
review of the effectiveness of QICs, Wells et al. (2017)
found some encouraging results [6]. However, the
authors also highlight the need to address significant,
persistent gaps in QIC design, quality of reporting, sus-
tainability and cost-effectiveness. A recent report from
New Zealand implies that BSCs can work within elective
joint replacement centres, although the effect could not
be separated from a natural improvement in healthcare
standards, as was happening prior to the intervention, in
part due to the before-and-after study design [7]. These
studies illustrate the complex nature of introducing any
change in practice and reinforce the need for further
high-quality evidence. The existing evidence demon-
strates the feasibility and potential effectiveness of QICs
and provides valuable insights for study design and out-
come measures.
Aims and objectives
The aim of the trial is to assess the clinical- and cost-
effectiveness of QICs, based on IHI BSC methodology,
to implement large-scale change in the NHS, specifically
for improving outcomes in patients undergoing elective
total hip and knee joint replacement. To achieve this, we
will compare the roll-out of two different improvement
initiatives, each initiative focussing on a different pre-
operative measure for improving post-operative out-
comes. These are, pre-operative anaemia management
(QIST: Anaemia) and pre-operative Methicillin Sensitive
Staphylococcus aureus (MSSA) decolonisation (QIST:
Infection).
The trial objectives are to measure patient-level out-
comes such as transfusion and infection rates, length of
stay in hospital, readmission rates and critical care admis-
sions; and process-of-care measures related to compliance
with elements of the quality improvement protocols.
QIST: Anaemia, implementing pre-operative anaemia
management
Pre-operative anaemia in patients undergoing elective
hip and knee replacement is associated with increased
post-operative morbidity and mortality, as well as in-
creased red blood cell transfusion rates, hospital read-
missions and a longer length of stay [8]. Patient Blood
Management (PBM) is a multidisciplinary approach
which aims to optimise the care of patients who may re-
quire a blood transfusion. A key element of this involves
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screening for, and correcting, anaemia and/or iron defi-
ciency pre-operatively. UK National and International
Guidance recommends the optimisation of anaemia
prior to surgery [9–11]. However, it is recognised that
implementation of pre-operative anaemia pathways is
challenging, leading to varying rates of their implemen-
tation [12, 13].
In the UK the 2015 National Comparative Audit of Blood
Transfusion was performed in 190 hospitals and stated that
hospitals should have a pre-operative management protocol
which allows for timely identification and treatment of
anaemia before elective surgery [14]. They concluded that
there is a need to increase the investigation and manage-
ment of pre-operative anaemia in the UK. They stated that
improvement in practice to help to ensure appropriate use
of transfusion and alternatives would benefit patients
and reduce healthcare costs. There are examples of
similar initiatives in Europe, the United States and
Australia [11, 15, 16].
The QIST: Anaemia arm of the trial aims to support
teams in developing and implementing pre-operative
anaemia-screening and -management pathways in their
local Trust through the use of a QIC. It is expected that
this will lead to a reduction in the number of patients
requiring peri-operative blood transfusion, the number
of units transfused and a reduced length of inpatient
stay. There is mixed evidence on the impact of anaemia
management on critical care admission and emergency
hospital readmission rates, and these will also be
assessed in this trial.
QIST: Infection, implementing pre-operative Methicillin
Sensitive Staphylococcus Aureus (MSSA) decolonisation
Total joint replacement (TJR) is increasing year on year
with an ageing population, with 252,251 cases being re-
corded in the UK National Joint Registry for the year
2017/2018 [17]. Surgical site infection (SSI) is a serious
and life-threatening complication of a TJR. Estimates of
SSI rates vary between 1 and 5% with the true rate likely
to be around 3% and 3.3% for total hip and knee replace-
ments, respectively [18]. Infection in a TJR can result in
prolonged antibiotic use, repeat operations and revision
surgery as well as fusion of the joint and amputation in
rare cases [19]. Patients who develop infection often
have a poor outcome, even when the infection has been
cleared. There is a heavy long-term burden on the pa-
tient and deep infections have a higher mortality rate
than prostate, breast and colorectal cancer at 5 years
[20]. Each deep infection costs up to £75,000 to treat
and, scaled up, the NHS cost of TJR SSI is approximately
£45 million per annum, based upon an average cost of
£10,000 per infection [21, 22].
Multiple systematic reviews and meta-analyses of
Staphylococcus aureus screening and decolonisation in
orthopaedic surgery have found this to be a cost-
effective method to reduce SSIs [23, 24]. In December
2016 the World Health Organisation recommended de-
colonisation of patients with nasal carriage of S. aureus
undergoing orthopaedic surgery, although this still rarely
occurs within the NHS [25].
The QIST: Infection arm of the trial aims to sup-
port teams in developing and implementing pre-
operative MSSA screening and/or decolonisation
pathways in their local Trust through the use of a
QIC. It is expected that this will lead to a reduction
in the number of patients suffering a post-operative
SSI (deep and superficial).
Anaemia and infection relationship
The trial assumes that the two primary outcomes, blood
transfusion and SSI, are independent and that the inter-
vention implemented in one trial arm does not affect the
outcome of the other, i.e. MSSA decolonisation does not
affect transfusion rates, and anaemia screening does not
affect SSI rates.
It is safe to assume that reducing SSIs would not affect
the rate of blood transfusion within 7 days of primary
surgery. SSIs typically take longer than this to develop
and, as such, any further surgery, i.e. revision arthro-
plasty, which may increase the risk of transfusion, would
be after this time. In one study the minimum time from
primary surgery to diagnosis of SSI was 11 days [26].
Conversely, there is evidence that being anaemic in-
creases the risk of a range of post-operative complica-
tions, including infection, and that improving anaemia
before surgery can reduce the risk of some of these com-
plications [8, 11]. However, what has not been estab-
lished is whether optimising anaemia pre-operatively
reduces post-operative SSI risk. It is theoretically pos-
sible that by improving anaemia in the QIST: Anaemia
arm of the trial we also reduce infection rates; however,
there is no evidence base for this from existing clinical
trials. In addition, it is expected that the effect size of
MSSA decolonisation in reducing SSI will be large
enough to still demonstrate a difference.
Iron treatment is often indicated to correct pre-
operative anaemia, this can be given orally or intraven-
ously [11]. There has been some concern that the use of
intravenously administered (IV) iron may potentially in-
crease infection rates as iron is a good medium for bac-
terial growth. However, a systematic review of clinical
trials has deemed there to be no evidence supporting
this theory [27]. In addition, it is anticipated that most
patients requiring iron treatment will take orally admin-
istered iron, with only a minority requiring IV iron [28].
Therefore, this is assumed to not be relevant to the
QIST trial.
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Rationale
Both pre-operative protocols are feasible and the pur-
pose of this cluster RCT is to establish whether they can
be introduced at pace and at scale in the English NHS
using a QIC approach. Trusts will be randomised to im-
plement one of the two initiatives for the duration of the
trial. Between Learning Sessions, teams will test and im-
plement changes in their local settings and collect data
to measure the impact change, supported by learning
and quality accounts. The Model for Improvement will
be applied as a way of testing small-scale improvement
cycles [4]. Following completion of the study period, all
Trusts will be given the opportunity to be trained in,
and implement, the alternate quality improvement
initiative.
The projected saving across 30,000 joint replacements
at 40 Trusts from the anaemia-screening initiative is
£4.8 million. From training 40 Trusts in MSSA screening
and decolonisation it is anticipated that infection will be
avoided in 0.5% of 30,000 joints, each costing an average
of £10,000, making a projected saving of £1.5 million.
The cost savings are in addition to the reduction in pain,
distress, mobility and morbidity issues for patients who
would otherwise have suffered these complications.
The choice of primary total hip and knee replacement
surgery for the trial is supported by the fact that these
are standard operations routinely undertaken in sizable
numbers in most NHS Trusts in England. There is exist-
ing supporting data for the planned protocols relevant to
total hip and knee replacement surgery, demonstrating
the potential for scalable effects across the NHS. Uni-
compartmental knee replacements and hip resurfacing
have been excluded as they are associated with lower
transfusion and infection rates compared to total hip
and knee replacements [29–32].
Methods
Study design
We will use a cluster randomised design which is the
most robust method to establish whether outcomes are
attributable to the quality improvement initiative, rather
than a secular trend. A RCT allows the control of known
and unknown variables in order that a causal relation-
ship can be established between an intervention and out-
come [33]. Because the quality improvement initiatives
that we are evaluating are targeted at healthcare teams,
it will be necessary to use a cluster RCT whereby Trusts
will be randomly allocated to one of the two groups.
The two study objectives related to anaemia and MSSA
will be addressed within a single RCT. The fact that all
hospitals will receive a quality improvement initiative
will enable us to address the ‘Hawthorne effect’ of taking
part in an implementation/research project [34]. So, any
difference in outcomes that we observe can be attributed
to the intervention rather than an ‘observation’ effect.
Study setting, population and recruitment
Working with NHS Improvement and the British Ortho-
paedic Association (BOA) we aim to recruit and ran-
domise 40 of the 139 acute NHS Trusts in England
performing elective total hip or knee replacement sur-
gery. Recruitment of sites will be through direct corres-
pondence with acute Trust chief executive officers and
clinical teams.
Eligibility and exclusion criteria
All English NHS acute Trusts performing elective pri-
mary total hip and/or total knee arthroplasty are eligible.
Trust executives must commit to providing consent to
participate if a Trust is recruited, as executive support
for the project form an early stage will be essential.
Trusts will be excluded if either it is already routine
practice for orthopaedic surgical patients to be screened
and/or managed for pre-operative anaemia or to be
screened and/or decolonised for MSSA.
Screening and pre-randomisation procedures
Trusts expressing an interest in participating will be
assessed against the inclusion and exclusion criteria for
eligibility.
If more than 40 NHS Trusts express an interest in taking
part in the study and are identified as suitable for inclusion,
selection will preference those performing a greater annual
number of hip and knee replacement procedures, as
reported by the National Joint Registry (NJR) [35].
Trusts identified as suitable for inclusion will be in-
formed and Trust-level consent to participate obtained.
Enrolment procedure
A contract between the sponsor and each participating
site, setting out the responsibilities of the sponsor, chief
investigator (CI) and site, including site principal investi-
gator (PI), will be in place. The contract will include re-
search permissions, clear governance and measurement
and communications protocols which will also help
build engagement and enthusiasm. An academic lead
and project manager will be identified for each site.
Sample size
There are limited published data on the specific rates of
post-operative MSSA SSI in England following a total
hip or knee replacement. In a large, randomised multi-
centre trial, the risk of developing hospital-associated
Staphylococcus aureus infection in MSSA-carrier pa-
tients who were decolonised on admission to hospital
(using mupirocin nasal ointment and chlorhexidine
soap) fell from 7.7 to 3.4% [36]. In a retrospective cohort
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study, performed by Northumbria Healthcare NHS
Foundation Trust, a decrease in MSSA infection rate
from 0.75% (28/3593) to 0.25% (23/9318) was found
following the adoption of an MSSA decolonisation
programme for carriers of MSSA in elective joint re-
placement [37]. To detect a difference from 0.75 to
0.25% would require 6246 patients in an individually
randomised trial with 80% power. Between October
2015 and September 2016, 123,861 hip and knee op-
erations were undertaken in 139 hospital Trusts
(average 891) [38]. Assuming an intraclass correlation
coefficient (ICC) of 0.005 [39], and a more conserva-
tive average of 750 patients per site, we require 40
sites to be recruited and randomised in this cluster
randomised trial.
Blood transfusion rates vary widely between hospi-
tals. Estimates suggest that hospitals’ transfusion rates
in the period from 28 days before surgery until 14
days post-operatively vary from < 10 to > 90% for total
hip replacement, with an overall rate of 25% [14].
Eighteen percent were transfused in the post-
operative period from 24 h to 14 days post-operatively
[14]. For total knee replacement, hospitals’ transfusion
rates vary from 0 to 39% (overall 19%) [40]. In rou-
tine total hip arthroplasty and total knee arthroplasty,
the prevalence of allogeneic red blood cell transfu-
sions has been reported to be between 21 and 70%,
with the majority of authors reporting figures in the
middle of the range [41].
In a prospective comparative cohort study of patients
from a single site who underwent elective hip and knee
arthroplasty before (control) and after (intervention) the
launch of the anaemia optimisation programme, it was
found that 3.9% (63/1622) of patients required an allo-
geneic red blood cell transfusion within 30 days follow-
ing surgery in the intervention group and 6.0% (108/
1814) in the control group [28]. With 40 sites, assuming
an ICC of 0.005, and an average of 750 patients per site,
we would have over 95% power to detect this difference
in transfusion rates.
Therefore, our sample size is for 40 Trusts, each
undertaking an average of 750 procedures per annum
and will be randomised on a 1:1 ratio. This sample is
powered to detect the smaller of the expected differ-
ences, a change in SSI rates.
Randomisation
Each participating NHS Trust will be treated as a cluster
and will be randomised 1:1 using minimisation by number
of hip and knee replacement procedures performed in a
12-month period, as reported by the NJR, (cut at the me-
dian) and the traffic-light indicators in the Learning From
Mistakes league table (outstanding/good/significant con-
cerns/poor) [42]. Minimisation will be via the dedicated
desktop application programme, MinimPy [43]. Trusts
will be randomised to receive either training on MSSA de-
colonisation to control post-operative infection or training
on the anaemia optimisation programme. The control
group for the anaemia optimisation quality improvement
initiative will be the other hospitals which will continue
with their usual practice for anaemia and vice versa, the
control group for MSSA will be the other hospitals who
will continue with their usual practice for MSSA. Each
Trust will be issued with a unique trial site identification
number at randomisation.
To minimise contamination or resentful demoralisa-
tion between the different quality improvement initia-
tive groups, which would reduce the possibility of
detecting important change (for example, an anaemia
initiative hospital trying to improve MSSA screening
at the same time), hospitals will be given the oppor-
tunity to be trained in the quality improvement initia-
tive that they have not received after the evaluation
period is over.
Blinding
Trusts and their nominated clinicians will be informed
of the quality improvement initiative to which they have
been randomised. It will not be possible to blind Trusts
or treating clinicians to the collaborative intervention or
their allocated quality improvement initiative. However,
the clinical team will take no part in the quantitative
assessment process. The functional outcome data will be
collected by Trust information teams and passed directly
to an independent company (e-Dendrite) for merging
and anonymisation.
Aggregated data will be fed back to Trusts as part of
the intervention process. A procedure for breaking codes
or un-blinding is, therefore, not necessary.
Intervention
The study intervention is a QIC based on the IHI BSC
model [4]. A collaborative is a short-term learning sys-
tem that brings together a large number of teams to
seek improvement in a focussed topic area and proven
intervention. Collaboratives provide a suitable vehicle
for delivery of a project at this scale, as they not only
aim to maximise local engagement and leadership but
are designed to build capacity, enable learning and
prepare for sustainability. The following intervention
description is in line with the TIDieR guidelines [44].
It is possible that what is ultimately delivered may dif-
fer as the collaborative programme evolves based on
the needs and feedback from participating sites.
TIDieR and SQUIRE guidelines will be used to assist
with detailed reporting of the intervention delivered in
the final report [44, 45].
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Key elements of the collaborative are detailed below
and summarised in Table 1.
Topic selection
‘Leaders identify a particular area or issue in
healthcare that is ripe for improvement: existing
knowledge is sound but not widely used, better results
have been demonstrated in real-world settings, and
current defect rates affect many patients somewhat, or
at least a few patients profoundly.’ [4]
For this project the two initiatives have demonstrated
real-world improvements in reducing SSI- and
anaemia-related complications, both of which have
profound effects on patients and their outcomes [28,
37]. However, these protocols are not widely used
across the NHS.
Faculty recruitment
‘Five to 15 experts are identified in the relevant
disciplines, including international subject matter
experts as well as application experts, individual
clinicians who have demonstrated breakthrough
performance in their own practice. One expert is
asked to chair the collaborative and is respon-
sible for establishing the vision of a new system
of care, providing faculty leadership, and teach-
ing and coaching the participating teams.’ ‘The
chair and the expert faculty assist in creating the
specific content for the collaborative, including
appropriate aims, measurement strategies and a
list of evidence-based changes. An Improvement
Advisor teaches and coaches teams on improve-
ment methods and how to apply them in local
settings.’ [4]
Table 1 Summary of how elements of Institute for Health Improvement Breakthrough Series Collaborative (IHI BSC) will be applied
to the Quality Improvement for Surgical Teams (QIST) trial
Elements of collaborative Planned approach/rationale for this study
Topic selection Real-world improvements seen with these MSSA and anaemia-screening protocols
They are not yet widely used across the NHS
Faculty recruitment CI and clinical lead trained in BSC methodology
Team of experts recruited to help guide project and advise teams at learning events
Enrolment of teams Calls for interested centres through BOA and NHS Improvement to all NHS Trusts in England to senior leaders,
management and clinicians to increase support and engagement
Selection procedure if more than 40 interested Trusts identified
All team members to be healthcare professionals and ideally GCP trained but this is not essential
Learning Sessions Separate dates for anaemia and MSSA learning sessions to avoid contamination
3 x 1-day, face-to-face group Learning Sessions per group
Attendees: experts, programme leads, improvement fellows, patient leaders and four study team members from
each Trust
Content: teach Trusts the relevant protocol, review evidence, governance arrangements, business cases,
communications, pathways, data collection and reporting arrangements
Further series of 3 Learning Sessions at the end of the study period to teach all Trusts both interventions
Action Periods Local teams implement change and collect data to measure the impact of change
Bespoke electronic data collection system will be developed and maintained throughout the study
Monthly progress reports will be sent to Trusts including number or operations performed compared to expected
activity
Learning Sessions will act as networking events for collaborative working and problem-solving
Study team members will be contactable for further advice as required
Summative congress
and publications
Initial summative session at the end of the 1st round of implementation for each separate trial arm
Final summative session to be held with all teams and collaborators invited
Results to be presented at BOA Congress 2020
Publication in high-impact journal will be sought
Potential influence on national guidelines
Measurement and evaluation Bespoke IT system will automatically generate near-to-live run charts and improvement metrics for individual teams
and the collaborative as a whole so that teams and faculty can track progress over time
BOA British Orthopaedic Association, BSC Breakthrough Series Collaborative, IT information technology, NHS National health Service, MSSA Methicillin Sensitive
Staphylococcus aureus
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The CI and clinical lead are trained in Breakthrough
Series methodology at IHI. The CI has used this
approach to improve hip fracture care with six NHS
organisations. The study team and collaborators include
a number of recognised experts of the two relevant
fields, namely prosthetic joint infection and pre-
operative anaemia management. We will draw on their
expertise to guide the development of the project and
provide expert advice at learning events and in overcom-
ing some barriers to local implementation of the
initiatives.
Enrolment of participating organisations and teams
‘Organisations elect to join a collaborative through
an application process, appointing multidisciplinary
teams within the organisation charged to learn from
the collaborative process, conduct small-scale tests of
change, and help successful changes become standard
practices. Senior leaders from participating
organisations are expected to guide, support, and
encourage the improvement teams, and to bear
responsibility for the sustainability of the teams’
effective changes.’ [4]
For this study, calls for interested centres will be made
via the British Orthopaedic Association (BOA) and via
the sponsor, Northumbria Healthcare NHS Foundation
Trust, with the help of NHS Improvement. This ap-
proach will target senior leaders, management and clini-
cians from each Trust to engage with, and be supportive
of, the improvement process. If more than the required
40 Trusts are interested preference will be given to those
performing greater numbers of hip and knee replace-
ment procedures per year. Local teams will consist of a
variety of healthcare professionals including orthopaedic
surgeons, haematologists, microbiologists, anaesthetists,
nurses and trainees. We will use existing surgical trainee
research collaboratives to spread word of the study and
encourage surgical trainee participation. The set-up
phase will be used to reflect upon the methodology,
build local engagement, enthusiasm and momentum and
prepare the measurement and reporting framework for
local performance data.
Learning Sessions
‘Traditional Learning Sessions are face-to-face
meetings, usually three of which are conducted
during a typical collaborative, bringing together
multidisciplinary teams from each organisation
and the expert faculty to exchange ideas. At the
first Learning Session, the expert faculty present a
vision for ideal care in the topic area and specific
changes, called a Change Package, that, when
applied locally, will improve significantly the system’s
performance. Teams learn from an Improvement
Advisor the Model for Improvement that enables teams
to test these powerful change ideas locally, and then
reflect, learn and refine these tests. At the second and
third Learning Sessions, team members learn even more
from one another as they report on successes, barriers
and lessons learned in general sessions, workshops,
storyboard presentations and informal dialogue and
exchange. Formal academic knowledge is bolstered by
the practical voices of peers who can say, “I had the
same problem; let me tell you how I solved it”.’ [4]
For this study we will be undertaking three 1-day, face-
to-face group Learning Sessions for each of the two arms
of the trial. During these events we will teach participat-
ing Trusts the relevant protocol depending on their ran-
dom trial allocation. We will also review the evidence,
governance arrangements, business cases, communica-
tion strategies, pathways, data collection and reporting
arrangements. These events will bring together experts,
programme leads, improvement fellows, patient leaders
and up to four study team members from each Trust to
encourage collaborative learning and aid local imple-
mentation of the quality improvement measures. The
learning events for the two groups will occur on separate
dates to reduce the risks of contamination. At the end of
the study period a further series of three learning events
will be run so that Trusts can be taught the second
protocol. This is intended to improve compliance, min-
imise crossover and maximise the benefit to Trusts in
being involved in the trial.
Action Periods
‘During Action Periods between the Learning
Sessions, teams test and implement changes in their
local settings — and collect data to measure the
impact of the changes. They submit monthly
progress reports for the entire collaborative to
review, and are supported by conference calls,
peer site visits and web-based discussions that
enable them to share information and learn from
national experts and other healthcare organisations.
The aim is to build collaboration and support the
organisations as they try out new ideas, even at a
distance.’ [4]
For this study, between Learning Sessions, teams will
test and implement changes in their local settings
and collect data to measure the impact change, sup-
ported by learning and quality accounts. The Model
for Improvement will be applied as a way of testing
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small-scale improvement cycles. Experience of this
work has taught us that reliable and regular measur-
ing of impact change together with providing timely
feedback to local teams has been key to successful
implementation.
A bespoke, secure, electronic data-extraction system
will be developed for this study. This will assist in
the production of monthly progress reports. An infor-
mation technology (IT) support line will be in place,
provided by e-Dendrite, our IT partner, for any IT is-
sues. Study team members will also be contactable for
any advice as required throughout the study period
and will explore various ways to encourage communi-
cation and collaboration between teams. The learning
events will act as networking opportunities for Trusts
to form working, collaborative relationships and
contacts.
Summative congresses and publications
‘Once the collaborative is complete, the work is
documented and teams present their results and
lessons learned to individuals from non-participating
organisations at national and international
conferences and meetings.’ [4]
For this study, a summative session will be held on com-
pletion of the implementation of the protocols for each
randomised arm. A second will be held after Trusts have
had the opportunity to introduce the alternate protocol,
to which all collaborators will be invited. The study re-
sults are due to be presented at the BOA National Con-
gress 2020 and publication in a high-impact journal will
be sought. There are potential links for the study results
to influence best practice tariffs and national guidelines.
Measurement and evaluation
‘Collaboratives involve regular measurement and
assessment. All teams are required to maintain
run charts tracking their system measures over
time and key faculty members review each team’s
monthly report to assess the overall progress of
the collaborative.’ [4]
The same bespoke, secure, electronic data-extraction
system will also provide near to live feedback to teams
on their Trust’s improvement journey. The system will
automatically generate a number of metrics and run
charts mapping the individual teams’ and whole collabo-
ratives’ improvement journey over time. An example
would be mapping the anaemia-screening rate per
month over time. This data can be used by the teams
and select faculty members.
Outcomes and measures
The trial will include quantitative and qualitative out-
come measures. The aim of this mixed-methods ap-
proach is to provide a detailed and robust evaluation of
the improvement collaboratives, addressing some of the
previously reported deficiencies in collaborative research.
To account for variation in clinical practice for issuing
blood transfusions between centres, the blood transfu-
sion policy from each will be collated and compared.
Quantitative outcomes and measures
We will collect patient-level outcomes and process
measure outcomes. Both arms of the trial must collect
all of the same patient-level outcomes to allow compari-
son between the two groups as they are acting as each
other’s control.
Patient-level outcomes
 Blood transfusion within 7 days before surgery or
7 days after surgery (primary outcome for QIST:
Anaemia)
 Deep SSI (MSSA) up to 90 days post surgery (using
the Public Health England (PHE) definition at 90
days, not 1 year) (primary outcome for QIST:
Infection)
 Deep SSI (any causative organism) and name of
pathogen (if known)
 Superficial infection up to 30 days post surgery, and
name of pathogen (if known)
 Length of hospital stay in days (number of
midnights spent in hospital)
 Readmission to hospital within 30 days of discharge
 Critical care admission within 30 days of surgery
(regardless of previous discharge)
 Time spent in critical care within 30 days of surgery
(number of midnights spent in the unit)
Process measures for QIST: Anaemia
 Date patient screened for anaemia
 Pre-operative blood results: haemoglobin (g/L),
ferritin (μg/L), estimated glomerular filtration rate
(eGFR) (mL/min/1.73 m2)
 Protocol functionality (follows Trust-agreed
protocol)
 Was iron given to the patient?
 If iron is given was this orally and/or intravenously
administered?
Process measures for QIST: Infection
 Date patient screened for MSSA
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 Results: ‘MSSA positive’ or ‘MSSA negative’ or ‘Not
tested’
 Protocol functionality (follows Trust-agreed
protocol)
 Date decolonising pack dispensed
 Confirmation used by the patient: Yes/No
In addition, patient comorbidity data will be collected
and presented in the description of surgical patients seen
at Trusts, and used in the economic evaluation.
Verification of surgical site infections
Identification
Identification of SSIs in the study population will
rely upon local follow-up measures, which may im-
prove by being part of the collaborative and local
reporting by orthopaedic trainees as part of the Na-
tional Collaborative Orthopaedic Research Network.
Orthopaedic trainees will have an understanding of
SSI from their clinical training. This will be built
upon with training around recording and auditing
data collected for the QIST trial. As an incentive to
report infections, etc., contributing trainees will be
included as collaborators on the outputs from the
trial.
Upon indication of any potential SSI, based on the
data entered into the QIST database, the recruiting site
will be contacted. If the treating clinical team diagnosed
a ‘deep infection’, prompt diagnosis and treatment of
this infection is fundamental to the patient’s routine
clinical care, so this will always be documented in the
patient’s medical record. Site staff will be asked to review
the patient’s medical records to provide additional
information. The site will be asked to provide com-
pletely redacted (hospital number only) copies of
relevant medical notes and any re-operation records
for surgery related to the index hip or knee arthro-
plasty; microbiology reports if samples of the sus-
pected infected tissues around the hip/knee were
sent for analysis; and/or imaging reports for any deep
imaging that occurred in relation to suspected infec-
tion. These data will be collated by the trial team in
York.
All Trusts should be able to reliably identify patients
who are readmitted to the same hospital within 90 days
of surgery. However, specialist centres that are likely to
perform a high proportion of operations take their pa-
tients from a wide area and are, therefore, not guaran-
teed to know whether patients are subsequently
admitted to a different, possibly more local hospital fol-
lowing surgery. We will, therefore, request readmission
data from NHS Digital via Hospital Episode Statistics
(HES) data.
Classification of SSI
Our initial intention was to use the Centres for Disease
Control (CDC) classification of infections, for which the
cut-off is 90 days. However, a number of Trusts are already
collecting infection data for PHE and are, therefore, more
familiar with the PHE classification than the CDC’s.
In discussion with the PHE Surgical Site Infection
Surveillance Team it was found that there were only
subtle differences between the CDC and PHE classifica-
tions. The main difference is in the time frame: 90 days
for CDC and 1 year for PHE. PHE has provided data
that demonstrate that using the PHE classifications and
cutting the data at 90 days (as for CDC and as planned
for this trial) would not make a significant difference in
identifying post-operative infections in our population
(Fig. 1).
It has, therefore, been agreed that the PHE classifica-
tion will be used by Trusts and the primary endpoint for
infection will remain at 90 days [46].
Confirmation of SSI
To confirm the robustness of the above reporting system
for identifying SSIs, an Independent Outcome Classifica-
tion (IOC) Group will be convened. This group will be
comprised of consultant revision hip and/or knee sur-
geons and consultant microbiologists. The IOC Group
will review all cases deemed to have a SSI (deep or
superficial, MSSA or other or unknown causative organ-
ism) as well as a purposeful sample of 50 cases where no
infection was reported. The IOC Group will be given ac-
cess to all the data collected by the research team as well
as relevant, redacted sections of the patient’s medical
records.
The IOC Group will use both the CDC and PHE clas-
sifications when reviewing cases to ensure that the
reporting of deep infection outcomes can be presented
to the wider international audience.
It is important to note that it is not uncommon for
the diagnosis of infection to be made in the absence of
positive microbiological findings. This may be due to the
concurrent administration of antibiotics for other infec-
tions, e.g. chest, or due to sampling error, or the bacteria
being hard to culture.
The medical records of those patients who die before
their primary outcome can be assessed will be reviewed
by the site team to understand whether SSI may have
had a contributory role to their death. It is expected that
this will be rare in our cohort and for the vast majority
this will not be the case, as most early deaths are related
to cardiovascular or respiratory events.
Qualitative process evaluation
The process evaluation will adopt a qualitative approach
to both the formative and summative elements of the
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Fig. 1 Public Health England (PHE) chart showing when a diagnosis of surgical site infections is made. Reproduced from Theresa Lamagni.
Epidemiology and burden of prosthetic joint infections. Journal of Antimicrobial Chemotherapy 2014;69 Suppl_1: i5–i10, doi: https://doi.org/10.
1093/jac/dku247. By permission of Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This figure is not
included under the Creative Commons license of this publication. For permissions, please contact journals.permissions@oup.comPlease
visit: https://academic.oup.com/jac/article/69/suppl_1/i5/772200?searchresult=1
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure for the Quality Improvement for Surgical Teams (QIST) trial
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evaluation of support. The formative evaluation will help
the project team to review and/or modify the improve-
ment/support plan should feedback indicate this is ne-
cessary. The summative element of the evaluation will
show where and whether the improvement programme
has been successful and met its objectives in the way
intended. The main evaluation questions are:
1. What has happened during the improvement
programme?
2. Were the various learning activities successful and
if so why?
3. Tell me about the support you have received
4. What has been the effect of being part of a BSC?
These will guide the choice of more specific evaluation
questions.
The learning events will be observed by the evaluator
and 80 semi-structured telephone interviews held with
team members from the participating Trusts throughout
the study. At the launch event teams will be given writ-
ten information about this evaluation.
Intervention delivery phase (November 2018 – April 2019)
Telephone interviews will be held with two members of
each of 10 teams (the project lead and one other team
member) in each trial arm (20 teams in all, 40 interviews).
Follow-up phase (November 2019 – March 2020)
Telephone interviews will be held with two members of
each of 10 teams in each intervention arm (the project
lead and one other team member) in each trial arm (20
teams in all, 40 interviews).
The second team member will be purposively selected
from those who volunteer, to reflect a spread of the vari-
ous health professionals involved in the quality improve-
ment initiatives (e.g. pre-assessment nurses, anaesthetists,
ward nursing staff, medical staff, infection control staff).
Verbal consent to recording the interviews and the use
of unattributed quotes will be sought prior to the inter-
views. Recording will be password-protected and encrypted.
Once transcribed, all recordings will be destroyed, and only
the anonymised transcripts retained. Throughout the
process the constant comparative method will be used to
identify commonalities and emerging patterns and themes
across sites.
This methodology and the evaluation questions should
enable a broad spread across all sites and provide rich
data to facilitate understanding of why and how using
BSCs as a quality improvement initiative are and are not
successful and may help to explain why the ‘same’ qual-
ity improvement initiatives may be implemented and
received in different ways in different sites.
Economic evaluation
The economic evaluation aims to assess the cost-
effectiveness of the quality improvement initiative for
MSSA and anaemia detection prior to elective total hip
and knee replacement. The objectives of our analyses
are to determine (1) the costs associated with the set-up,
administration and delivery of both improvement initia-
tives; (2) whether the improvement initiatives lead to
cost savings in terms of NHS healthcare resource use;
and (3) whether the improvement initiatives lead to fur-
ther benefits in terms of patients’ improved health. The
analyses will be conducted from the perspective of the
NHS and for the duration of the trial.
The economic costing of the quality improvement ini-
tiative represents the primary objective of this evalu-
ation. The costs will be analysed from a NHS and
Personal Social Services (PSS) perspective. We will con-
sider all resource use during the set-up, process adminis-
tration and delivery of the quality improvement
initiative. A resource-use survey will be specifically de-
signed for the QIST trial to capture a comprehensive list
of inputs associated with the quality improvement initia-
tive both at Trust and patient level. Both staff and non-
staff or material costs (e.g. equipment investments, in-
formation technology and consumables) will be consid-
ered in the analysis. Staff time associated with the
delivery of the programme will be valued using national
unit costs per working hour for each Agenda for Change
band of staff. Unit costs for the analysis will be derived
from established national costing sources such as NHS
Reference Costs, PSS Research Unit costs of health and
social care, and the British National Formulary.
Secondary outcomes for the trial will be used to assess
the cost-savings associated with the qualitative improve-
ment initiative (e.g. hospital readmission, length of hos-
pital stay, readmissions and critical care admission,
regardless of previous discharge). Besides, transfusions
and infection rates will be used to assess the cost-
effectiveness of the improvement initiatives. Sensitivity
analyses will be undertaken to explore and quantify any
uncertainty around economic estimates.
Analysis and reporting
A detailed statistical analysis plan for the analysis of
quantitative data will be prepared and signed off by the
Trial Steering Committee prior to data analysis. Analysis
will be conducted using the principles of intention to
treat, i.e. patients and Trusts will be analysed in the
group to which they were randomised, irrespective of
whether or not they actually received, or adhered to,
their allocated quality improvement initiative. Further
per-protocol and case analyses will also be performed.
Statistical significance will be assessed using two-sided
tests at the 5% level. The flow of NHS Trusts and
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patients/procedures through the trial will be presented
in a Consolidated Standards of Reporting Trials (CON-
SORT) flow diagram [47].
The primary analyses will, separately, compare transfu-
sion and deep infection rates between the quality improve-
ment initiative and control groups at the procedure level
using a mixed-effects logistic regression model. The
models will adjust for pertinent baseline covariates at the
patient/procedure level (e.g. procedure type, age, gender
of patient) and at the Trust level (e.g. the minimisation
factors used in the randomisation), with NHS Trust as a
random effect. Adjusting for baseline factors likely to be
predictive of outcome, e.g. procedure type, will increase
the precision of the estimated treatment effects. The exact
model specifications will be agreed prior to the comple-
tion of data extraction, and pre-specified in the statistical
analysis plan. We shall analyse at the level of the proced-
ure, rather than the patient, since it is possible that a small
number of patients will undergo more than one eligible
procedure during the study period. We will treat the pro-
cedures as independent, and conduct sensitivity analyses
retaining only the earliest procedure for each patient to as-
sess the impact of duplicate patients on the results. We
anticipate that any impact will be minimal. The secondary
outcomes of superficial infection, hospital readmission,
length of stay and critical care admission will be analysed
using appropriate regression techniques based on the type
of data.
Data on processes (e.g. compliance with elements of
each of the quality improvement protocols such as pro-
portion of eligible patients tested for MSSA; proportion
of decolonising packs dispensed; proportion screened for
anaemia; proportion of patients with anaemia treated
before surgery) will be summarised descriptively by
treatment group.
Analyses and results will be reported in accordance
with the CONSORT extension for cluster trials [47].
Project data portal
A bespoke data portal for the project will be developed
within the secure N3 NHS network. e-Dendrite is an
NHS-verified supplier, and it currently provides national
audit tools for all NHS Trusts in England and, therefore,
is considered a trusted third party.
Fully anonymised aggregated data will be fed back to
each Trust via the Quality Improvement Team, on a
monthly basis.
A fully anonymised dataset of historical Patient Ad-
ministration System (PAS) data for each Trust for the
12months prior to the intervention period will be sent
by secure means to a secure server at York Trials Unit
(YTU). A fully anonymised patient dataset and Trust-
level aggregated dataset at the first extraction month
after the start of the trial will be supplied to YTU to
check the quality of data and data collection. A fully
anonymised patient-level dataset and Trust-level aggre-
gated dataset will be sent to YTU’s secure server at the
end of the intervention period.
Patient and public involvement
We sought the views of patients and the public on the
use of health information without explicit patient con-
sent for this study. Members of a total hip replacement
patient representative group (THUG) were unanimously
comfortable with hospitals being randomised as a Trust
and not obtaining individual patient-level consent. Real-
time feedback from 16 inpatients gave unequivocal sup-
port for health information being used in this way.
The Trial Steering Committee membership will in-
clude a patient representative. The THUG group have
agreed to remain involved and will be given regular up-
dates on progress and asked to comment on relevant
documentation as appropriate.
In addition, a patient representative will be included in
the co-production of the Learning Sessions, contributing
to both the development and the delivery of the
sessions.
Ethics and governance
The study is sponsored by the Northumbria Healthcare
NHS Foundation Trust.
Written information on the qualitative evaluation will
be distributed to NHS staff at the first learning events.
Verbal consent will be sought from NHS staff prior to
recording the qualitative interviews. Once transcribed,
all recordings will be destroyed, and only the anonymised
transcripts retained. Interviews will be recorded and tran-
scribed verbatim. Verbal permission will also be sought
from interviewees to use unattributed quotes in reports
and/or publications resulting from this programme.
Patient-level consent will not be sought as the intro-
duction of the anaemia and infection screening proce-
dures are quality improvement initiatives and both have
been demonstrated to be effective and recommended for
use across the NHS [10, 25].
The intervention is targeted at Trust level and NHS
research ethics approval is not required. Institutional ap-
proval was sought from the Health Sciences Research
Governance Committee of the University of York; the
committee felt that research ethics approval was not
necessary for this study (reference no: HSRGC/2018/
256/D). HRA approval was sought and obtained (IRAS
238457).
An application to the Confidential Advisory Group is
not necessary as the only identifier to be used when
transferring data from Trusts to e-Dendrite will be the
local Hospital Number. Data passed from e-Dendrite to
the Quality Improvement Team and to YTU will be fully
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anonymised. Within each of the Trusts, data will be
collected by staff members who already have permission
to access the patient data as part of their role.
The trial will comply with the principles of the Declar-
ation of Helsinki, and be conducted in accordance with the
principles of Good Clinical Practice. This protocol has been
reported in accordance with SPIRIT guidelines (Fig. 2).
Discussion
Successful implementation of pre-operative anaemia op-
timisation for elective hip and knee replacement patients
has been achieved and positive results reported from at
least one NHS Trusts in England [28]. This work
showed that a relatively straightforward clinical pathway
including the use of orally administered and/or IV iron
resulted in significant reductions in the number of pa-
tients transfused (6 v 4.1% p = 0.005), length of hospital
stay (3.9 v 3.6 days p = 0.017), critical care admissions
(1.27 v 0.55% p = 0.03) and hospital readmissions (4.5%
v 3.0% p = 0.02). This was found to be cost-effective,
resulting in savings of £162.46 per patient screened, or
£406,000 for a Trust performing 2500 primary THR or
TKRs per annum.
Similarly, a relatively simple programme for pre-operative
MSSA screening and decolonisation has also been success-
fully implemented in an English NHS Trust for elective hip
and knee arthroplasty patients [37]. This resulted in a sig-
nificant reduction in the rate of MSSA prosthetic joint in-
fection (0.75 v 0.25% p < 0.0001). This programme is
reported to have prevented 47 MSSA prosthetic infections
and cost £1893 per infection avoided, each of which would
have cost tens of thousands of pounds to treat.
It is expected that Trusts will see similar benefits from
anaemia and MSSA screening programmes by being part
of the QIST trial.
The scale of the proposed project brings considerable
challenges and potential barriers to delivery [48]. We ex-
pect these challenges to include recruiting and sustain-
ing 40 organisations, each with its own culture and
context, and dealing with multiple stakeholders across a
large geographical area. The project will be managed by
a strong team with a proven track record including:
project leadership at a senior level, advanced project
management and governance and supported by an expe-
rienced research team at YTU. The participatory, collab-
orative implementation methodology of the BSC model
provides the opportunity for flexibility in implementa-
tion to reflect contexts of individual participating Trusts.
Trial status
At the time of submission, we are working to Protocol
Version 1.5 dated 18 March 2019. Recruitment began in
October 2017 and was completed May 2018 when 41
Trusts were randomised.
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